KRAS activating mutations represent the most prevalent oncogenic drivers in lung adenocarcinoma, occurring in approximately 25% to 32% of cases across both early and advanced stages of the disease [5], whereas these mutations are detected in less than 1% of squamous cell carcinoma cases [6]. The gene discussed is KRAS; the disease is lung adenocarcinoma.